People searching "ibogaine pacific palisades" are usually asking two things at once: can I get this here, and can it be done safely? This guide answers both plainly for Pacific Palisades, then explains the medically supervised alternative most patients choose.

The Legal Picture in Pacific Palisades
No. Federal Schedule I status and the absence of any California exemption mean no Pacific Palisades physician or facility can lawfully administer ibogaine. Ibogaine is listed at the highest control level in the United States under 21 U.S.C. § 812, meaning no clinic anywhere in the country may lawfully administer it outside an authorised research protocol. That single fact explains why legitimate ibogaine care is delivered abroad, in jurisdictions where it can be provided inside a regulated medical facility.
What the Unregulated Market Looks Like
Discreet in-home providers occasionally serve Westside families who want privacy above all. Privacy and safety are not the same purchase: a private setting without telemetry and a physician is the highest-risk way to take ibogaine.
- No pre-treatment ECG or QT-interval assessment
- No magnesium and potassium correction before dosing
- No continuous cardiac telemetry and no physician on site
- No liver function panel or drug-interaction review
- No aftercare — the highest-risk window is the days that follow

The Supervised Alternative
Sanctuary Tulum operates in Tulum, Mexico as a facility licensed by COFEPRIS, Mexico's federal health regulator. Every course of ibogaine treatment begins with cardiac screening and bloodwork, proceeds under physician supervision with continuous monitoring, and continues into structured recovery support rather than ending at discharge. Over more than a decade of medically supervised administration, the facility has maintained a zero-fatality record — notable given documented deaths at unregulated clinics elsewhere.
LAX is about 30 minutes away, then 5 to 7 hours to Cancún with one connection. For most Pacific Palisades patients the deciding factor is not travel — it is whether a physician and a cardiac monitor are in the room. See how ibogaine for fentanyl detox is handled clinically, read the cardiac safety screening protocol, or start with the Sanctuary Tulum homepage.
Cardiac Safety: What Screening and Monitoring Actually Involve
Ibogaine's primary risk is cardiac, not psychiatric. Ibogaine and its metabolite noribogaine block the cardiac potassium channel responsible for repolarising the heart between beats, prolonging the QT interval; a sufficiently prolonged QT interval can trigger torsades de pointes, a potentially fatal arrhythmia. Recent case reports of ibogaine-induced cardiac arrest make the mechanism concrete rather than theoretical, which is why every stage of a medically supervised program is built around cardiac clearance rather than treated as a formality.
Before any dosing decision at a licensed facility, patients undergo a 12-lead ECG to establish baseline QTc, a comprehensive metabolic panel with specific attention to magnesium and potassium — both corrected to normal range before treatment, since low levels of either independently prolong the QT interval — and a liver panel, since ibogaine is metabolised hepatically and impaired clearance extends the risk window. A physician also reviews every current medication for QT-prolonging interactions. During the dosing window itself, continuous cardiac telemetry lets the clinical team see rhythm changes in real time, a physician remains present at bedside rather than on call, and a documented emergency protocol — including resuscitation equipment and ACLS-trained staff — is in place before the first dose is given. That sequence is exactly what recent cardiac case literature identifies as absent in the fatal and near-fatal cases reported outside supervised settings.
Who Ibogaine Treatment Is — and Isn't — Appropriate For
Ibogaine is generally considered for adults with opioid dependence or other treatment-resistant substance use who clear a full cardiac and psychiatric screening — normal QTc, corrected electrolytes, no unmanaged structural heart disease, and no medication that cannot be safely paused. It is not appropriate for patients with a QT interval that cannot be corrected, significant unmanaged cardiac disease, pregnancy, severe hepatic impairment, or anyone unwilling to complete the full pre-treatment workup. A responsible program will decline to dose a patient who does not clear screening, even after travel from Pacific Palisades has already been arranged — that willingness to say no is itself a safety signal worth asking about directly.
Preparation Decides the Outcome
Ibogaine is not a one-day event. Screening happens weeks ahead; short-acting opioid transition, electrolyte repletion and nervous-system support come before dosing; and integration, nutrition and follow-up care come after. That full sequence — not the dose itself — is what separates a medical program from a hotel-room administration.
Continue through this regional series with Ibogaine Toronto, or read the preceding guide on Ibogaine Malibu. For the full clinical picture see ibogaine treatment in Mexico.
Medical & Educational Disclaimer
This page is educational and does not diagnose, treat or replace care from a licensed physician. Ibogaine carries documented cardiac and drug-interaction risks and should only be considered within a medically supervised setting after a full clinical evaluation.

What Pre-Treatment Cardiac Screening Actually Involves
Ibogaine's cardiac risk is not theoretical, and a responsible program treats it as the central safety question rather than a footnote. A resting ECG is taken before any dosing decision is made, specifically to measure the QT interval — the portion of the heart's electrical cycle that ibogaine is known to prolong. Electrolyte panels are checked because low magnesium or potassium can compound that risk, and both are corrected in advance of treatment when needed. A liver panel is also standard, since ibogaine is metabolized hepatically and impaired liver function changes how the drug clears the body.
During dosing itself, continuous cardiac telemetry allows the clinical team to see real-time changes and intervene immediately if the rhythm becomes abnormal. This is the single detail most absent from underground administration, and it is the reason documented ibogaine deaths have occurred almost exclusively outside supervised medical settings. None of this eliminates risk entirely — no medical intervention does — but it converts an unmonitored gamble into a managed clinical procedure with a trained team positioned to respond.
The Days Before and After Matter as Much as the Dose
Patients arriving from Pacific Palisades and the wider Westside are often managing an opioid dependency that took years to develop, and a single ibogaine session is not treated as a standalone event. In the days before treatment, short-acting opioid transition and nutritional support prepare the body for dosing. Afterward, structured integration, nervous-system support and a written aftercare plan give the physiological reset a better chance of holding. Guests considering this pathway alongside a broader recovery plan can review our medically supervised detox program and luxury rehab pages for how the surrounding clinical support is structured.
Anyone evaluating a facility for this work should ask directly what cardiac monitoring equipment is on site, who the supervising physician is, and what the documented emergency protocol says. A program confident in its safety record will answer without hesitation.
References
- Controlled Substances Act, 21 U.S.C. § 812, Schedule I(c) (ibogaine).
- Alper KR, et al. Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci. 2012;57(2):398-412.
- Koenig X, Hilber K. The anti-addiction drug ibogaine and the heart: a delicate relation. Molecules. 2015;20(2):2208-2228.
- Brunt TM, et al. Rare but relevant: ibogaine and cardiovascular complications — prolonged QT interval and ventricular arrhythmias. Addiction. 2026;121(6):1616-1621.
- Mestre D, et al. Multiple episodes of cardiac arrest induced by treatment with ibogaine: a case report. Cureus. 2024;16(6):e63487.
- Noller GE, et al. Ibogaine treatment outcomes for opioid dependence from a twelve-month follow-up observational study. Am J Drug Alcohol Abuse. 2018;44(1):37-46.
- COFEPRIS — Mexico's federal health regulator.

